At present, the S1PR modulators used in IBD mainly include non‐specific regulators such as FTY720 and specific regulators such as ozanimod (targeting S1PR1 and S1PR5), etrasimod (targeting S1PR1) and amiselimod (targeting S1PR1 and S1PR5), which have entered phase II or III clinical trials or approved for IBD. Here, S1PR1 is linked to inflammatory bowel disease.